Quest Diagnostics Q2 FY26 diluted EPS rises 15% to 2.84; revenue increases 10.2% to 3.04 billion

Quest Diagnostics Incorporated

Quest Diagnostics Incorporated

DGX

0.00
  • Quest Diagnostics posted Q2 net revenues of USD 3.04 billion, up 10.2% year over year, with reported diluted EPS of USD 2.84, up 15%.
  • Adjusted diluted EPS under non-GAAP climbed 19.1% to USD 3.12, while reported operating income rose 4.6% to USD 459 million.
  • Requisition volume increased 13.1%, while revenue per requisition fell 2.8%.
  • Highlights included double-digit Advanced Diagnostics growth, New York State approval for Haystack MRD, and a larger rollout of lab automation and IntelliDraw.
  • Full-year guidance was raised to net revenues of USD 11.95 billion-USD 12.05 billion, reported diluted EPS of USD 9.97-USD 10.17.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quest Diagnostics Incorporated published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607230645PR_NEWS_USPR_____NY10225) on July 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.